Allestimento di modelli sperimentali di alcaptonuria e valutazione preclinica di agenti terapeutici per il trattamento dell’artropatia ocronotica
- 3 Anni 2010/2013
- 241.200€ Totale Fondi
L'alcaptonuria è una malattia rara a base genetica per la quale non esiste cura. E' asintomatica fino ai 40 anni circa, dopodichè rapidamente si manifestano problemi a vari organi, ma soprattutto a livello delle articolazioni. Abbiamo sviluppato modelli sperimentali umani su cui sperimentare nuovi farmaci e proponiamo la sperimentazione pre-clinica di acetilcisteina, un farmaco la cui sicurezza è garantita da oltre 40 anni di uso clinico e che potrebbe essere utilizzato anche nella prevenzione di bambini geneticamente affetti, nonché altri tipi di farmaci.
Pubblicazioni Scientifiche
- 2010 JOURNAL OF CELLULAR BIOCHEMISTRY
Proteomic and Redox-Proteomic Evaluation of Homogentisic Acid and Ascorbic Acid Effects on Human Articular Chondrocytes
- 2015 JOURNAL OF INHERITED METABOLIC DISEASE
Amyloidosis in alkaptonuria
- 2015 Journal of cellular physiology
Chondroptosis in Alkaptonuric Cartilage
- 2012 Journal of cellular physiology
Biochemical and proteomic characterization of alkaptonuric chondrocytes
- 2011 JOURNAL OF INHERITED METABOLIC DISEASE
Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis
- 2012 BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Alkaptonuria is a novel human secondary amyloidogenic disease
- 2014 MEDIAT INFLAMM
Amyloidosis, Inflammation, and Oxidative Stress in the Heart of an Alkaptonuric Patient
- 2014 DIAGNOSTIC PATHOLOGY
Diagnosis of secondary amyloidosis in alkaptonuria
- 2015 Journal of cellular physiology
Establishment of Four New Human Primary Cell Cultures from Chemo-Naive Italian Osteosarcoma Patients
- 2015 JOURNAL OF INHERITED METABOLIC DISEASE
Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria
- 2015 J BIOSCIENCES
Human platelet releasates combined with polyglycolic acid scaffold promote chondrocyte differentiation and phenotypic maintenance
- 2013 RHEUMATOLOGY
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria
- 2014 INTERNATIONAL JOURNAL OF CARDIOLOGY
Secondary amyloidosis in an alkaptonuric aortic valve
- 2015 FREE RADICAL BIOLOGY AND MEDICINE
Oxidative stress and mechanisms of ochronosis in alkaptonuria
- 2013 Expert Review of Proteomics
Redox proteomics gives insights into the role of oxidative stress in alkaptonuria
- 2011 FOOD MICROBIOLOGY
Surfome analysis of a wild-type wine Saccharomyces cerevisiae strain
- 2012 Journal of cellular physiology
Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: Implications in alkaptonuria
- 2012 BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Alkaptonuria is a novel human secondary amyloidogenic disease.
- 2017 Biochim Biophys Acta.
Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins.
